Cancer Research, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.
Department of Gastroenterology and Hepatology, Flinders Medical Centre, Adelaide, South Australia, Australia.
J Gastroenterol Hepatol. 2022 Jun;37(6):1067-1075. doi: 10.1111/jgh.15823. Epub 2022 Mar 16.
Surveillance colonoscopies may be delayed because of pressure on resources, such as the COVID-19 pandemic. This study aimed to determine whether delayed surveillance colonoscopy increases the risk for advanced neoplasia and whether interval screening with faecal immunochemical tests (FITs) and other known risk factors can mitigate this risk.
A retrospective cohort study of individuals undergoing surveillance colonoscopy for personal or family history of colorectal neoplasia was being provided with FIT between colonoscopies. Colonoscopy ≥ 6 months after the guideline-recommended interval was considered "delayed." Individuals were stratified based on prime colonoscopy findings to nonneoplastic findings, non-advanced adenoma, and advanced adenoma. The relative risk (RR) for developing advanced neoplasia was determined using a robust multivariable modified Poisson regression.
Of 2548 surveillance colonoscopies, 1457 (57.18%) were delayed. Prior advanced adenoma, older age (> 60 years) and nonparticipation in interval FIT were associated with increased risk for advanced neoplasia (P < 0.05). There was a trend to increased risk in those with prior advanced adenoma with an increasing colonoscopy delay (P trend = 0.01). In participants who did not complete interval FIT and having advanced adenoma in the prime colonoscopy, risk of advanced neoplasia was 2.48 times higher (RR = 2.48, 95% confidence interval: 1.20-5.13) in participants who had beyond 2 years of delayed colonoscopy compared with those with on-time colonoscopy. Colonoscopy delay did not increase the risk of advanced neoplasia in participants with negative interval FIT results.
Surveillance colonoscopy can be safely extended beyond 6 months in elevated colorectal cancer risk patients who do not have prior advanced adenoma diagnosis, particularly if interval FIT is negative.
由于资源压力,如 COVID-19 大流行,监测结肠镜检查可能会被推迟。本研究旨在确定延迟监测结肠镜检查是否会增加高级别肿瘤的风险,以及间隔期进行粪便免疫化学检测(FIT)和其他已知风险因素筛查是否可以降低这种风险。
对因个人或家族结直肠癌病史而进行监测结肠镜检查的个体进行了一项回顾性队列研究,这些个体在结肠镜检查之间接受了 FIT 检查。如果结肠镜检查的间隔时间超过指南建议的时间≥6 个月,则被认为是“延迟”。根据主要结肠镜检查结果将个体分为非肿瘤性发现、非高级别腺瘤和高级别腺瘤。使用稳健的多变量修正泊松回归确定发生高级别肿瘤的相对风险(RR)。
在 2548 例监测结肠镜检查中,1457 例(57.18%)被延迟。先前的高级别腺瘤、年龄较大(>60 岁)和未参加间隔期 FIT 与高级别肿瘤的风险增加相关(P<0.05)。在先前有高级别腺瘤的患者中,随着结肠镜检查延迟时间的增加,风险呈上升趋势(P 趋势=0.01)。在未完成间隔期 FIT 且在主要结肠镜检查中发现高级别腺瘤的患者中,与按时接受结肠镜检查的患者相比,延迟超过 2 年的患者发生高级别肿瘤的风险高 2.48 倍(RR=2.48,95%置信区间:1.20-5.13)。在间隔期 FIT 结果为阴性的患者中,结肠镜检查延迟不会增加高级别肿瘤的风险。
在没有先前高级别腺瘤诊断的结直肠癌风险升高的患者中,监测结肠镜检查可以安全地延长至 6 个月以上,特别是如果间隔期 FIT 为阴性。